Skip to main content
. Author manuscript; available in PMC: 2021 Apr 20.
Published in final edited form as: Acc Chem Res. 2020 Oct 5;53(10):2094–2105. doi: 10.1021/acs.accounts.0c00456

Figure 5.

Figure 5.

(A) sHDL-DOX is formed by incubation of lipid-DOX with preformed sHDL. (B) Ultrasmall size and prolonged circulation of sHDL enable intratumoral delivery of DOX. Released DOX kills tumor cells and triggers ICD, promoting the recruitment of DCs and antigen-specific T cells. Antitumor immunity primed with sHDL-DOX synergizes with immune checkpoint blockade, leading to efficient elimination of established tumors and prevention of tumor relapse. (C) Immunization scheme of MC38 study with sHDL-DOX. (D) Frequency of neoantigen-specific CD8+ T cells among PBMCs. (E) Tumor growth curves of mice treated with indicated formulations. (F) Lung metastasis of MC38 cells after IV tumor rechallenge. Reproduced with permission from ref 5. Copyright 2018 American Association for the Advancement of Science.